CA2211400A1 - Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin - Google Patents
Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutyninInfo
- Publication number
- CA2211400A1 CA2211400A1 CA002211400A CA2211400A CA2211400A1 CA 2211400 A1 CA2211400 A1 CA 2211400A1 CA 002211400 A CA002211400 A CA 002211400A CA 2211400 A CA2211400 A CA 2211400A CA 2211400 A1 CA2211400 A1 CA 2211400A1
- Authority
- CA
- Canada
- Prior art keywords
- desethyloxybutynin
- oxybutynin
- urinary incontinence
- treating urinary
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A method for treating urinary incontinence while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering a therapeutically effective amount of (S)-oxybutynin, (S)-desethyloxybutynin or a pharmaceutically acceptable salt thereof, substantially free of the corresponding R enantiomer. Pharmaceutical compositions in the form of tablets and transdermal devices comprising (S)-oxybutynin or (S)-desethyloxybutynin and an acceptable carrier are also disclosed, as is a synthesis of desethyloxybutynin.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/381,542 US5532278A (en) | 1995-01-31 | 1995-01-31 | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin |
US08/381,542 | 1995-01-31 | ||
US08/480,194 | 1995-06-07 | ||
US08/480,194 US5677346A (en) | 1995-01-31 | 1995-06-07 | Treating urinary incontinence using (S)-desethyloxybutynin |
PCT/US1996/001053 WO1996023492A1 (en) | 1995-01-31 | 1996-01-25 | Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2211400A1 true CA2211400A1 (en) | 1996-08-08 |
CA2211400C CA2211400C (en) | 2007-01-23 |
Family
ID=27009434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002211400A Expired - Fee Related CA2211400C (en) | 1995-01-31 | 1996-01-25 | Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin |
Country Status (25)
Country | Link |
---|---|
US (1) | US5677346A (en) |
EP (1) | EP0806948B1 (en) |
JP (1) | JPH11511730A (en) |
KR (1) | KR100390271B1 (en) |
CN (1) | CN1151786C (en) |
AT (1) | ATE196252T1 (en) |
AU (1) | AU706741B2 (en) |
BR (1) | BR9607001A (en) |
CA (1) | CA2211400C (en) |
CZ (1) | CZ290093B6 (en) |
DE (1) | DE69610290T2 (en) |
DK (1) | DK0806948T3 (en) |
ES (1) | ES2150663T3 (en) |
FI (1) | FI973163A (en) |
GR (1) | GR3034974T3 (en) |
HK (1) | HK1017986A1 (en) |
HU (1) | HUP9800794A3 (en) |
NO (1) | NO315927B1 (en) |
NZ (1) | NZ303372A (en) |
PL (1) | PL182768B1 (en) |
PT (1) | PT806948E (en) |
RU (1) | RU2181589C2 (en) |
SK (1) | SK283313B6 (en) |
UA (1) | UA45387C2 (en) |
WO (1) | WO1996023492A1 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736577A (en) * | 1995-01-31 | 1998-04-07 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin |
US6171298B1 (en) | 1996-05-03 | 2001-01-09 | Situs Corporation | Intravesical infuser |
JP2001502302A (en) * | 1996-09-19 | 2001-02-20 | アメリカン・ホーム・プロダクツ・コーポレイション | How to treat urinary incontinence |
US6123961A (en) * | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
WO1999033454A2 (en) * | 1997-12-31 | 1999-07-08 | Sepracor Inc. | S-procyclidine for treating urinary incontinence |
US6183461B1 (en) | 1998-03-11 | 2001-02-06 | Situs Corporation | Method for delivering a medication |
US6013830A (en) * | 1998-03-30 | 2000-01-11 | Sepracor Inc. | Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols |
CZ302630B6 (en) * | 1998-08-27 | 2011-08-10 | Pharmacia & Upjohn Ab | Pharmaceutical composition containing tolterodine or tolterodine-related compound |
AU767877B2 (en) | 1999-05-20 | 2003-11-27 | Sepracor, Inc. | Methods for treatment of asthma using S-oxybutynin |
US6432446B2 (en) * | 2000-02-03 | 2002-08-13 | Bridge Pharma, Inc. | Non-arrhythmogenic metabolite of oxybutynin |
US6521724B2 (en) | 2000-03-10 | 2003-02-18 | E. I. Du Pont De Nemours And Company | Polymerization process |
US6436428B1 (en) | 2000-03-21 | 2002-08-20 | Enhance Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
CN101305994A (en) | 2000-04-26 | 2008-11-19 | 沃特森药物公司 | Minimizing adverse experience associated with oxybutynin therapy |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
JP5684964B2 (en) * | 2000-06-07 | 2015-03-18 | ワトソン ファーマシューティカルズ, インコーポレイテッド | Treatment of smooth muscle hyperfunction with (R) -oxybutynin and (R) -desethyloxybutynin |
WO2002011768A1 (en) * | 2000-08-03 | 2002-02-14 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
DE10060550C1 (en) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for administration of oxybutynin, especially for treatment of bladder dysfunction, having two-phase matrix layer of active agent-containing droplets dispersed in adhesive |
DE10103262A1 (en) * | 2001-01-25 | 2002-08-01 | Axel Schmidt-Dossi | Suppository containing oxybutynin, useful for treatment of incontinence, avoids side effects and allows an increase in dose |
EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
CN1536986B (en) * | 2001-03-27 | 2012-07-04 | 沃纳奇尔科特(爱尔兰)有限公司 | Intravaginal drug delivery devices for administration of antimicrobial agent |
US20030027856A1 (en) * | 2001-06-29 | 2003-02-06 | Aberg A.K. Gunnar | Tolterodine metabolites |
CA2464217A1 (en) * | 2001-11-05 | 2003-05-15 | Pharmacia & Upjohn Company | Antimuscarinic aerosol |
US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
US7921999B1 (en) * | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
EP1455776A4 (en) * | 2001-12-21 | 2006-05-17 | Bridge Pharma Inc | A non-arrhythmogenic metabolite of oxybutynin |
DE60204229T2 (en) * | 2002-12-02 | 2006-02-02 | Schwarz Pharma Ag | Administration of rotigotine for the treatment of Parkinson's disease by iontophoresis |
AU2004283431B2 (en) | 2003-10-10 | 2009-09-10 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
US8415390B2 (en) | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
KR20150011379A (en) * | 2007-05-30 | 2015-01-30 | 마이크로도스 테라퍼스, 인코포레이티드 | Methods and compositions for administration of oxybutynin |
US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
EA030145B1 (en) | 2010-08-03 | 2018-06-29 | Велисепт Терапьютикс, Инк. | Combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
CN104684549A (en) | 2012-02-09 | 2015-06-03 | 奥瑟克斯公司 | Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder |
JP2012176958A (en) * | 2012-04-20 | 2012-09-13 | Watson Pharmaceuticals Inc | Treatment of smooth muscle hyperactivity by (r)-oxybutynin and (r)-desethyloxybutynin |
US20140135392A1 (en) * | 2012-11-13 | 2014-05-15 | NeuRx Pharmaceuticals LLC | Methods for the treatment of sialorrhea |
US20160151321A1 (en) | 2012-11-13 | 2016-06-02 | Dinesh C. Patel | Methods for the treatment of sialorrhea |
CN104116760A (en) * | 2014-07-14 | 2014-10-29 | 玉庆花 | An oral liquid for treating enuresis |
KR20170086659A (en) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
FI3365321T3 (en) | 2015-10-23 | 2024-01-02 | B3Ar Therapeutics Inc | Solabegron zwitterion and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL267508A (en) * | 1960-07-26 | |||
BE902605A (en) * | 1985-06-06 | 1985-09-30 | Therabel Res S A N V | Medicaments for treating urinary tract disorders - contg. oxybutynin chloride |
PT100502A (en) * | 1991-05-20 | 1993-08-31 | Alza Corp | PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE CAPACITY OF PERMEACAO IN THE SKIN USING GLYCEROL MONOLINOLEATE |
JP3066515B2 (en) * | 1992-11-11 | 2000-07-17 | 久光製薬株式会社 | Transdermal formulation for treatment of urinary incontinence |
CA2165802A1 (en) * | 1993-09-29 | 1995-04-06 | Eun Soo Lee | Monoglyceride/lactate ester permeation enhancer for oxybutynin |
-
1995
- 1995-06-07 US US08/480,194 patent/US5677346A/en not_active Expired - Fee Related
-
1996
- 1996-01-25 CZ CZ19972421A patent/CZ290093B6/en not_active IP Right Cessation
- 1996-01-25 KR KR1019970705184A patent/KR100390271B1/en not_active IP Right Cessation
- 1996-01-25 EP EP96906202A patent/EP0806948B1/en not_active Expired - Lifetime
- 1996-01-25 UA UA97084420A patent/UA45387C2/en unknown
- 1996-01-25 DK DK96906202T patent/DK0806948T3/en active
- 1996-01-25 HU HU9800794A patent/HUP9800794A3/en unknown
- 1996-01-25 RU RU97114572/14A patent/RU2181589C2/en not_active IP Right Cessation
- 1996-01-25 ES ES96906202T patent/ES2150663T3/en not_active Expired - Lifetime
- 1996-01-25 NZ NZ303372A patent/NZ303372A/en unknown
- 1996-01-25 DE DE69610290T patent/DE69610290T2/en not_active Expired - Fee Related
- 1996-01-25 BR BR9607001A patent/BR9607001A/en not_active IP Right Cessation
- 1996-01-25 CN CNB961928891A patent/CN1151786C/en not_active Expired - Fee Related
- 1996-01-25 WO PCT/US1996/001053 patent/WO1996023492A1/en active IP Right Grant
- 1996-01-25 PL PL96321498A patent/PL182768B1/en not_active IP Right Cessation
- 1996-01-25 CA CA002211400A patent/CA2211400C/en not_active Expired - Fee Related
- 1996-01-25 AU AU49664/96A patent/AU706741B2/en not_active Ceased
- 1996-01-25 AT AT96906202T patent/ATE196252T1/en not_active IP Right Cessation
- 1996-01-25 JP JP8523636A patent/JPH11511730A/en not_active Ceased
- 1996-01-25 PT PT96906202T patent/PT806948E/en unknown
- 1996-01-25 SK SK1035-97A patent/SK283313B6/en unknown
-
1997
- 1997-07-30 FI FI973163A patent/FI973163A/en not_active IP Right Cessation
- 1997-07-30 NO NO19973516A patent/NO315927B1/en unknown
-
1998
- 1998-10-13 HK HK98111210A patent/HK1017986A1/en not_active IP Right Cessation
-
2000
- 2000-11-24 GR GR20000402596T patent/GR3034974T3/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2211400A1 (en) | Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin | |
CA2257121A1 (en) | Methods and compositions for treating urinary incontinence using optically pure (s)-oxybutynin | |
CA2215329A1 (en) | Colorectal chemoprotective composition and method for preventing colorectal cancer | |
CA2309027A1 (en) | Method for treating hypercholesterolemia with unsubstituted polydiallylamine | |
CA2180535A1 (en) | A method for treatment of psoriasis, by omeprazole or related compounds | |
AU684053B2 (en) | Compositions of L-DOPA esters | |
NZ504618A (en) | Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level | |
RO116342B1 (en) | Oral liquid pharmaceutical composition | |
MY129473A (en) | 3,3-diarylpropylamines, their use and preparation | |
CA2259012A1 (en) | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders | |
WO2000071108A3 (en) | Methods for treatment of asthma using s-oxybutynin | |
CA2113916A1 (en) | 6-Chloro-5-Fluoro-3-(2-Thenoyl)-2-Oxindole-1-Carboxamide as an Analgesic and Anti-Inflammatory Agent | |
WO1999033450A3 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
CA2283255A1 (en) | Use of r-nsaid's for the prevention of alzheimer's disease | |
WO2003002059A3 (en) | Tolterodine metabolites | |
WO2001000187A3 (en) | Pharmaceutical composition containing sibutramine and a lipase inhibitor | |
WO1996021670A3 (en) | Antifungal fusacandins | |
WO1999033454A3 (en) | S-procyclidine for treating urinary incontinence | |
WO2000076490A3 (en) | Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin | |
WO1999033453A3 (en) | R-procyclidine for treating urinary incontinence | |
AU1305999A (en) | (+)-ephedrine as a sympathomimetic drug | |
IE840198L (en) | Therapeutic use of nafazatrom | |
JO1738B1 (en) | A new therapeutically active compound | |
GB9508482D0 (en) | A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product | |
MY110416A (en) | Composition for the treatment of schizophrenia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |